Exclusive NICE chiefs have agreed to accept a second round of feedback on updated type 2 diabetes clinical recommendations, after their original draft guidance was branded ‘bonkers’ by GP experts.
NICE said it was opening a second consultation on Friday 26 June after ‘universal’ requests from stakeholders – despite previously insisting there were no grounds for a second consultation.
Professor Mark Baker, director of clinical practice at NICE, told Pulse that after further consideration the regulator agreed a new consultation ‘was the right thing to do’ after so many changes were made to the original document.
The draft guidelines caused widespread dissent from diabetes experts over revamped advice on glucose-lowering treatments, which they said was nonsensical and based too much on cutting costs, and risked making NICE ‘a laughing stock’.
Professor Roger Gadsby, a GPSI in diabetes, said that experts were branding the guidance ‘bonkers’, while an editorial in the British Journal of Diabetes and Vascular Care said the guidance would ‘set back modern diabetes management by decades’.
NICE informed stakeholders last month that ‘substantive’ revisions had been made to the draft recommendations after the initial consultation on the recommendations – but said no further consultation was needed as no new analyses had been conducted.
But Pulse has learned that after giving the request ‘further consideration’, NICE has now agreed to open the revised version for further scrutiny.
Professor Baker said: ‘We’ve given further consideration to the requests from our stakeholders for a second consultation on the draft type 2 diabetes guideline. We have agreed that holding a second consultation on the updated section of the draft guideline is the right thing to do, in view of the number of changes made to proposals on the therapies for managing diabetes, and the universal stakeholder requests to see the changes.
‘We’ve updated our stakeholders to let them know that this focused consultation will run from 26 June until 24 July, and we hope that this extra step will further reassure stakeholders of the robustness of our proposed recommendations.’
Dr David Millar-Jones, chair of the Primary Care Diabetes Society (PCDS), which led the calls for a second consultation, said it was ‘great news’ that NICE had changed tack.
Dr Millar-Jones said: ‘The PCDS has been concerned that the original draft guidance would be subject to confusion and place patients at risk.
‘We drafted a letter to NICE expressing our concerns. This was supported by other organisations who are leaders in clinical management. Despite little acknowledgement and several emails asking for review of the “substantive changes” that we were told had been made, we are delighted that this has now been put forward for a further consultation.
‘We look forward to reviewing the new therapeutic advice and hope that it is a document that we can now support.’